Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Jazyk angličtina Země Itálie Médium electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
38572549
PubMed Central
PMC11290529
DOI
10.3324/haematol.2023.284678
Knihovny.cz E-zdroje
- MeSH
- COVID-19 * mortalita komplikace MeSH
- dexamethason * terapeutické užití MeSH
- dospělí MeSH
- farmakoterapie COVID-19 * MeSH
- hematologické nádory * mortalita farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- registrace * MeSH
- SARS-CoV-2 * izolace a purifikace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- dexamethason * MeSH
Aristotle University of Thessaloniki Thessaloniki Greece
Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo Alessandria
Azienda Ospedaliera Sant'Anna e San Sebastiano Caserta
Azienda Sanitaria Universitaria del Friuli Centrale Udine
Centre Hospitalier d'Argenteuil Argenteuil
Department of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria
Department of Hematology CH Sud Francilien Corbeil Essonnes
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology Hospital Universitario de Burgos Burgos
Department of Hematology Research Unit Hospital Universitario de Burgos Burgos
Department of Hematology University Hospital Dubrava Zagreb Croatia
Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden
Department of Internal Medicine ADRZ Goes
Department of Medicine A Hematology Oncology and Pneumology University Hospital Munster Munster
Department of Mental Health and Public Medicine University of Campania Naples
Department of Nephrology and Infectious diseases AZ Sint Jan Brugge Oostende AV Brugge
Division of Hematology and Oncology Weill Cornell Medicine New York
Divisione Clinicizzata di Ematologia Ospedale Ferrarotto Catania
Dokuz Eylul University Division of Hematology Izmir
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan
Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD Madrid
General Hospital of Thessaloniki George Papanikolaou Thessaloniki Greece
Haematology Dept Dimiccoli Hospital Barletta
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome
Hematology and Stem Cell transplant Unit Vito Fazzi Lecce
Hematology and Stem Cell Transplantation Unit AOUC Policlinico Bari
Hematology Department Hospital General Universitario Gregorio Maranon Madrid
Hematology Department Hospital Universitario de Salamanca Salamanca
Hematology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome
Hematology Unit ASST Ospedali Civili Brescia
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome
Hospital Escuela de Agudos Dr Ramon Madariaga Posadas
Hospital Nuestra Senora de Sonsoles Avila
Hospital Universitario Infanta Leonor Madrid
Hospital University of Parma Hematology and Bone Marrow Unit Parma
Infektiologie Universitatsklinikum Frankfurt am Main Frankfurt am Main
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Ospedale San Raffaele Milan
Istituto Oncologico della Svizzera Italiana Bellinzona Switzerland
La Paz University Hospital Madrid Spain; CIBERINFEC Instituto de Salud Carlos 3 Madrid
Medizinische Klinik 2 Klinikum rechts der Isar TU Munchen Munich
Memorial Cancer Hospital and Research Centre Lahore
Northumbria Healthcare Newcastle
Oncology Center Mansoura University Mansoura Egypt
Portuguese Institute of Oncology Lisbon
San Luigi Gonzaga Hospital Orbassano Orbassano
University Clinic of Hematology Skopje North Macedonia
University Clinical Center Serbia Medical Faculty University Belgrade Belgrade Serbia
University Medical Center Groningen Groningen
Zobrazit více v PubMed
Cesaro S, Ljungman P, Mikulska M, et al. . Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36(6):1467-1480. PubMed PMC
Pan H, Peto R, Henao-Restrepo AM, et al. . Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. PubMed PMC
Aiello TF, Puerta-Alcalde P, Chumbita M, et al. . Infection with the Omicron variant of SARS-CoV-2 is associated with less severe disease in hospitalized patients with COVID-19. J Infect. 2022;85(5):e152-e154. PubMed PMC
Garcia-Vidal C, Moreno-García E, Hernández-Meneses M, et al. . Personalized therapy approach for hospitalized patients with coronavirus disease 2019. Clin Infect Dis. 2022;74(1):127-159. PubMed PMC
Hedberg P, Karlsson Valik J, Van Der Werff S, et al. . Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data. Thorax 2022;77(2):1-10. PubMed PMC
Garcia-Vidal C, Alonso R, Camon AM, et al. . Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. Journal of Antimicrobial Chemotherapy 2021;76(12):3296-3302. PubMed PMC
Blennow O, Salmanton-García J, Nowak P, et al. . Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2002;97(8):E312-E317. PubMed PMC
Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25)2881-2892. PubMed PMC
Sharma A, Bhatt NS, St Martin A, et al. . Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193. PubMed PMC
Horby P, Lim WS, Emberson JR, et al. . Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. PubMed PMC
Abani O, Abbas A, Abbas F, et al. . Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023;401(10387):1499-1507. PubMed PMC
Camon AM, Alonso R, Muñoz FJ, et al. . C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Sci Rep 2022;12(1):5250. PubMed PMC
Aiello T-F, Puerta-Alcalde P, Chumbita M, et al. . Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals. J Antimicrob Chemother. 2023;78(6):1454-1459. PubMed
Mikulska M, Sepulcri C, Dentone C, et al. . Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77(2):280-286. PubMed
Salmanton-García J, Marchesi F, Gomes da Silva M, et al. . Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. EClinicalMedicine. 2023;58:101939. PubMed PMC
